Testicular Cancer (Nutritional Support)
Most curable solid tumor in young men requiring cisplatin-based chemotherapy support, fertility preservation nutrition, and long-term cardiovascular and metabolic health monitoring
Overview
Testicular cancer is the most common solid tumor in men aged 15–35 years (~9,500 new cases/year in the US) and the most curable solid tumor — overall 5-year survival >95%. Germ cell tumors (GCTs) account for >95% of testicular cancers: seminoma (~55%) and non-seminomatous germ cell tumors (NSGCTs — embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, ~45%). Cryptorchidism is the strongest risk factor (3–8x increased risk). Five-year survival: ~99% (stage I), ~96% (stage II), ~73% (stage III). Treatments: radical orchiectomy (diagnostic and therapeutic), surveillance (stage I seminoma/NSGCT — preferred over adjuvant therapy in low-risk), adjuvant carboplatin (stage I seminoma), adjuvant BEP chemotherapy (stage I NSGCT high-risk), BEP chemotherapy (bleomycin + etoposide + cisplatin — standard for metastatic GCTs; 3–4 cycles), EP chemotherapy (etoposide + cisplatin — for good-risk disease), VIP (vinblastine + ifosfamide + cisplatin — salvage), TIP (paclitaxel + ifosfamide + cisplatin — salvage), high-dose chemotherapy + autologous stem cell transplant (HDCT/ASCT — for relapsed/refractory GCTs). 2025–2026 advances: TIGER trial final analysis (2024) — TI-CE HDCT vs conventional TIP salvage: no OS benefit overall but benefit in platinum-sensitive relapse; HDCT/ASCT remains standard for multiply relapsed GCTs; pembrolizumab for cisplatin-refractory GCTs (KEYNOTE-158: 4% ORR — limited activity in GCTs due to low TMB and immunosuppressive tumor microenvironment); enfortumab vedotin (Nectin-4 ADC) showing early activity in refractory GCTs in Phase I/II; nivolumab + ipilimumab for refractory GCTs (KEYNOTE-158 expansion: 11% ORR — modest but meaningful in this setting); genomic profiling (KRAS, TP53, MDM2, CDK4/6 amplification) guiding salvage therapy selection; circulating tumor DNA (ctDNA) for minimal residual disease monitoring post-chemotherapy; long-term survivor care guidelines updated 2024 — cardiovascular risk reduction, metabolic syndrome screening, and secondary malignancy surveillance now formalized; cabazitaxel for refractory GCTs in Phase II trials. Nutritional rationale: cisplatin causes severe nausea, nephrotoxicity, hypomagnesemia, hypokalemia, peripheral neuropathy, and ototoxicity; bleomycin causes pulmonary toxicity (bleomycin-induced pneumonitis — avoid high FiO2); etoposide causes bone marrow suppression; fertility preservation is critical before chemotherapy (sperm banking); long-term survivors have increased cardiovascular risk, metabolic syndrome, and secondary malignancy risk from cisplatin and radiation.
Evidence highlight: BEP chemotherapy achieves >95% cure rate in good-risk metastatic GCTs (Williams et al., 1987). TIGER trial (2024): TI-CE HDCT vs conventional TIP salvage — no OS benefit overall; HDCT/ASCT remains standard for multiply relapsed GCTs. Nivolumab + ipilimumab: 11% ORR in cisplatin-refractory GCTs (KEYNOTE-158 expansion). Cisplatin-induced hypomagnesemia occurs in >90% of patients — IV magnesium supplementation is standard of care during BEP cycles. Alpha-lipoic acid reduces cisplatin-induced peripheral neuropathy in RCTs (Gedlicka et al., 2003). CoQ10 is concentrated in sperm mitochondria and improves sperm motility in infertile men (Balercia et al., 2009). Long-term cardiovascular risk elevated 2–3x in testicular cancer survivors treated with cisplatin (Haugnes et al., 2010). Sperm banking before treatment preserves fertility — azoospermia occurs in 30–50% of patients after BEP chemotherapy.
Core Nutrition Principles
- 1Cisplatin causes severe hypomagnesemia, hypokalemia, and nephrotoxicity — aggressive magnesium, potassium, and fluid repletion (2–3 liters/day) is critical during and after BEP chemotherapy
- 2Fertility preservation is the most important pre-treatment consideration — sperm banking before orchiectomy and chemotherapy is mandatory; nutritional support for sperm quality (zinc, selenium, CoQ10, vitamin C, vitamin E)
- 3Bleomycin causes pulmonary toxicity (bleomycin-induced pneumonitis) — avoid high-dose supplemental oxygen; antioxidants may reduce bleomycin pulmonary toxicity; monitor pulmonary function
- 4Cisplatin-induced peripheral neuropathy is a major long-term toxicity — alpha-lipoic acid, acetyl-L-carnitine, and B vitamins support nerve function and may reduce neuropathy severity
- 5Long-term cardiovascular risk is significantly elevated in testicular cancer survivors — cisplatin causes endothelial damage, dyslipidemia, and metabolic syndrome; Mediterranean diet, omega-3, and CoQ10 are essential for long-term cardiovascular protection
- 6Testosterone deficiency occurs after orchiectomy (bilateral) or radiation — testosterone replacement therapy (TRT) may be needed; zinc and vitamin D support testosterone production in the remaining testis
- 7High protein intake (1.5–2g/kg/day) supports muscle mass in young men during chemotherapy — leucine-rich proteins and BCAAs are particularly important
- 8Gut microbiome diversity supports immunotherapy response and chemotherapy tolerance — high-fiber diet and probiotics are essential during BEP chemotherapy
Priority Foods
- High-quality protein (chicken, turkey, eggs, Greek yogurt, lean beef) — 1.5–2g/kg/day; muscle preservation during chemotherapy; support for young men maintaining lean mass; leucine-rich for muscle protein synthesis
- Wild-caught fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; cardiovascular protection (critical for long-term survivors); anti-inflammatory; anti-cachexia; sperm quality support
- Banana, sweet potatoes, and avocado — potassium replacement for cisplatin-induced hypokalemia; magnesium; healthy fats; calorie-dense
- Nuts and seeds (pumpkin seeds, almonds, walnuts, Brazil nuts) — magnesium, zinc, selenium; counteract cisplatin-induced hypomagnesemia; sperm quality support; antioxidants
- Leafy greens (spinach, kale, arugula) — folate, magnesium, antioxidants; DNA repair; anti-inflammatory; gut microbiome support
- Berries (blueberries, raspberries, strawberries) — antioxidants; anti-inflammatory; gut microbiome support; reduce cisplatin oxidative stress
- Whole grains (oats, quinoa, brown rice) — fiber; B vitamins; gut microbiome support; energy; low-glycemic
- Fermented foods (kefir, yogurt, kimchi) — gut microbiome diversity; reduce chemotherapy GI toxicity; immune support
- Ginger tea and ginger chews — reduce cisplatin-induced nausea (most severe nausea of any chemotherapy); anti-inflammatory; soothing
- Turmeric with black pepper — curcumin; anti-tumor; anti-inflammatory; NF-kB inhibition; antioxidant
- Pomegranate juice — antioxidants; anti-tumor; cardiovascular protection; sperm quality support
Core Supplements
- Magnesium glycinate — 600–800mg daily; cisplatin causes severe hypomagnesemia (occurs in >90% of patients); muscle cramps; nausea; cardiac arrhythmia risk; monitor serum magnesium closely; IV magnesium may be needed during BEP cycles
- Omega-3 EPA/DHA — 3–4g daily; cardiovascular protection for long-term survivors; anti-inflammatory; anti-cachexia; sperm quality support; reduce cisplatin-induced endothelial damage
- CoQ10 (ubiquinol) — 300–600mg daily; cardiovascular protection; mitochondrial support; sperm quality (CoQ10 is concentrated in sperm mitochondria); reduces cisplatin-induced fatigue; antioxidant
- Alpha-lipoic acid (ALA) — 600–1,200mg daily; reduces cisplatin-induced peripheral neuropathy; antioxidant; nerve function support; use R-ALA form for better bioavailability
- Acetyl-L-carnitine — 1,000–2,000mg daily; reduces cisplatin-induced peripheral neuropathy; nerve function; mitochondrial support; sperm motility support
- Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); immune support; cardiovascular protection; testosterone support; anti-tumor; target 60–80 ng/mL
- Zinc picolinate — 30–50mg daily; sperm quality and testosterone production in remaining testis; immune function; wound healing post-orchiectomy; antioxidant; max 50mg/day with 2mg copper
- Selenium (selenomethionine) — 200mcg daily; sperm quality; antioxidant; immune support; may reduce cisplatin toxicity
- Vitamin C (liposomal) — 2,000–4,000mg daily; antioxidant; reduces cisplatin nephrotoxicity; immune support; sperm quality; collagen synthesis for wound healing
- Vitamin E (mixed tocopherols) — 400 IU daily; antioxidant; reduces bleomycin pulmonary toxicity; sperm quality; cardiovascular protection
- Probiotics (50 billion CFU multi-strain) — gut microbiome diversity; reduce BEP chemotherapy GI toxicity; immune support; Lactobacillus rhamnosus GG + Bifidobacterium longum
- B-complex (activated) — B12 (methylcobalamin 1,000mcg), B6 (P5P 50mg), folate (5-MTHF 800mcg); nerve function; DNA repair; energy metabolism; reduce cisplatin neuropathy
Treatment Protocols
- Radical inguinal orchiectomy — diagnostic and therapeutic; inguinal approach (NOT scrotal) to avoid lymphatic disruption; provides pathological diagnosis and staging; sperm banking BEFORE surgery if bilateral or chemotherapy planned
- Sperm banking — MANDATORY before orchiectomy and chemotherapy; fertility preservation; testicular cancer and chemotherapy can cause azoospermia; bank multiple samples; discuss with reproductive urologist
- Surveillance (stage I) — preferred for low-risk stage I seminoma and NSGCT; avoids overtreatment; requires compliance with CT and tumor marker monitoring every 3–6 months for 5 years
- Adjuvant carboplatin (stage I seminoma) — single dose AUC 7; reduces relapse from 15–20% to 3–5%; alternative to surveillance for patients preferring treatment
- BEP chemotherapy — bleomycin (30 units IV weekly) + etoposide (100mg/m2 days 1–5) + cisplatin (20mg/m2 days 1–5); 3 cycles for good-risk; 4 cycles for intermediate/poor-risk; standard for metastatic GCTs since 1977
- EP chemotherapy — etoposide + cisplatin (no bleomycin); for good-risk patients with pulmonary risk factors (prior lung disease, smokers); equivalent efficacy to BEP in good-risk disease
- RPLND (retroperitoneal lymph node dissection) — for stage II NSGCT or post-chemotherapy residual mass; nerve-sparing technique preserves ejaculation in >95% of cases
- Salvage chemotherapy (TIP or VIP) — paclitaxel + ifosfamide + cisplatin (TIP) or vinblastine + ifosfamide + cisplatin (VIP); for relapsed/refractory GCTs
- HDCT/ASCT — high-dose carboplatin + etoposide + autologous stem cell transplant; for multiply relapsed GCTs; curative in 15–25% of patients
- Tumor marker monitoring — AFP (alpha-fetoprotein), beta-hCG, LDH; before orchiectomy, after orchiectomy, and throughout treatment; marker normalization confirms complete response
- Long-term cardiovascular surveillance — annual blood pressure, lipid panel, fasting glucose, BMI; cisplatin causes metabolic syndrome in 30–40% of survivors; Mediterranean diet + exercise essential
- Testosterone monitoring — annual testosterone levels; hypogonadism in 15–20% of survivors; TRT if symptomatic and testosterone <300 ng/dL; zinc and vitamin D support endogenous testosterone
- Secondary malignancy surveillance — increased risk of contralateral testicular cancer (2–5%), leukemia (etoposide), and solid tumors (radiation); annual self-examination; follow-up with oncologist
- TIGER trial (2024) — TI-CE HDCT vs conventional TIP salvage: no OS benefit overall; HDCT/ASCT remains standard for multiply relapsed GCTs; benefit in platinum-sensitive relapse subgroup; results clarify patient selection for HDCT
- Nivolumab + ipilimumab for refractory GCTs — KEYNOTE-158 expansion: 11% ORR in cisplatin-refractory GCTs; modest but meaningful activity in this highly refractory population; option after 2+ prior lines
- Enfortumab vedotin — Nectin-4 ADC; Phase I/II activity in refractory GCTs; Nectin-4 expressed in ~30% of GCTs; investigational; same agent approved for urothelial carcinoma
- ctDNA monitoring — circulating tumor DNA for minimal residual disease detection post-chemotherapy; emerging tool for early relapse detection; more sensitive than AFP/hCG/LDH in some cases
- Updated long-term survivor guidelines (2024) — formalized cardiovascular risk reduction, metabolic syndrome screening, secondary malignancy surveillance, and hypogonadism management protocols for testicular cancer survivors
- Pulmonary function monitoring during bleomycin — PFTs before each cycle; discontinue bleomycin if DLCO falls >25%; avoid high FiO2 anesthesia post-bleomycin
Foods & Substances to Avoid
- Alcohol during BEP chemotherapy — hepatotoxic; worsens cisplatin nausea and nephrotoxicity; impairs bone marrow recovery; interacts with etoposide metabolism; complete avoidance during treatment
- Smoking — associated with increased testicular cancer risk; worsens bleomycin pulmonary toxicity; impairs cardiovascular health in long-term survivors; cessation mandatory
- NSAIDs (ibuprofen, naproxen) — interact with cisplatin (reduce renal clearance, increase nephrotoxicity); use acetaminophen for pain during BEP chemotherapy
- High-dose supplemental oxygen post-bleomycin — bleomycin sensitizes lungs to oxygen toxicity; avoid FiO2 >30% during anesthesia; inform all anesthesiologists of bleomycin history
- Grapefruit with etoposide — CYP3A4 inhibition increases etoposide levels and toxicity
- Dehydration — cisplatin is severely nephrotoxic; adequate hydration (2–3 liters/day) is mandatory during and after cisplatin cycles; monitor urine output
- High-sodium diet — worsens cisplatin-induced hypertension and fluid retention; target <2,000mg sodium/day during chemotherapy
- Raw or undercooked foods during neutropenia — infection risk during etoposide-induced bone marrow suppression; neutropenic diet required during chemotherapy nadir
- Processed foods and refined sugar — promote inflammation and metabolic syndrome; particularly important to avoid long-term given elevated cardiovascular risk in testicular cancer survivors
- Anabolic steroids — impair spermatogenesis in remaining testis; worsen cardiovascular risk; avoid completely
Get your personalized protocol
Take the full assessment to receive a protocol tailored to your specific symptoms and goals.
Start AssessmentKey Nutrients
Drug & Supplement Interactions
Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.
- •Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
- •Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
- •Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2
- •Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
- •Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR
- •Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
- •Warfarin — high-dose vitamin A may increase anticoagulant effect
- •Orlistat — reduces fat-soluble vitamin absorption including vitamin A
- •Cholestyramine — reduces vitamin A absorption
- •Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
- •Phenytoin and phenobarbital — B6 may reduce drug levels
- •Statins — combination increases risk of myopathy; use with caution
- •Diabetes medications — high-dose niacin may impair glucose control
- •Blood pressure medications — additive vasodilatory effect
- •Antibiotics (tetracyclines, fluoroquinolones) — magnesium reduces absorption; separate by 2+ hours
- •Bisphosphonates (alendronate) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Diuretics — thiazide diuretics increase magnesium excretion; loop diuretics may deplete magnesium
- •Digoxin — magnesium deficiency increases digoxin toxicity risk; supplementation may be protective
- •Muscle relaxants — additive effect; may increase sedation
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Bisphosphonates — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
- •Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
- •Cyclosporine — may reduce drug levels; monitor in transplant patients
- •Warfarin — may reduce anticoagulant effect; monitor INR
- •Blood pressure medications — additive hypotensive effect
- •Chemotherapy — may interact with certain agents; consult oncologist
- •Statins — statins deplete CoQ10; supplementation is generally recommended
- •Thyroid medications — L-carnitine may reduce thyroid hormone activity; monitor TSH
- •Warfarin — may increase anticoagulant effect; monitor INR
- •Valproate (anticonvulsant) — valproate depletes carnitine; supplementation may be needed
- •Thyroid medications — may reduce thyroid hormone activity; monitor TSH
- •Warfarin — may increase anticoagulant effect; monitor INR
- •Valproate — depletes carnitine; supplementation may be needed
- •Warfarin — may increase anticoagulant effect; monitor INR
- •Thyroid medications — may affect thyroid hormone activity
- •Cholinesterase inhibitors (Alzheimer's medications) — additive cholinergic effect; monitor
- •Antibiotics (tetracyclines, fluoroquinolones) — zinc reduces antibiotic absorption; separate by 2+ hours
- •Copper — high-dose zinc (>40mg/day) depletes copper; supplement 1–2mg copper per 30mg zinc
- •Iron supplements — compete for absorption; separate by 2+ hours
- •Penicillamine (for rheumatoid arthritis) — zinc reduces drug absorption
- •Thiazide diuretics — increase zinc excretion
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
- •Copper — high-dose zinc depletes copper
- •Chemotherapy (cisplatin) — may reduce drug effectiveness; consult oncologist
- •Anticoagulants — high doses may have mild antiplatelet effect
- •Statins — may interact with statin metabolism at high doses
- •Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
- •Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
- •Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
- •Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
- •Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
- •Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses
- •Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
- •Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
- •Statins — may reduce statin effectiveness at very high doses
- •Cyclosporine — may reduce drug levels
- •Niacin — high-dose combination may reduce HDL-raising effect of niacin
- •Warfarin — high doses (>1g/day) may reduce anticoagulant effect
- •Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
- •Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
- •Statins — very high doses may reduce statin effectiveness
- •Aluminum antacids — vitamin C increases aluminum absorption; avoid combination
- •Metformin — long-term use depletes B12; supplementation is recommended
- •PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
- •Chloramphenicol — may reduce B12 effectiveness
This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.
Related Conditions
This protocol is for informational purposes only. Consult a qualified healthcare provider before making dietary or supplement changes.